Adjuvant Chemoradiation for Localized Gastric Adenocarcinoma: AnInstitutional Experience

cancer with locoregional relapse in 40% to 60%. The frequency of relapses makes regional radiotherapy an attractive possibility for adjuvant therapy. The survival benefit of adjuvant chemoradiation over surgery alone was first established by the US Intergroup 0116 study. Patients and methods: Between January 2010 and December 2014, 48 patients with localized gastric adenocarcinoma, managed at radiotherapy department of the national institut of oncology, they underwent adjuvant chemoradiation according the classical MacDonald regimen. Results: This series consisted of non-metastatic patients, 68.8% (33) males with a mean age 51 years. 20.8% (10) of patients had relapses (all distant relapse). 22 (45.8%) patients died, only 8(16.6%) patients were lost to follow up. Almost all patients complete full course chemoradiation. The median follow-up duration was 25.4 (15.6- 48) months. The 5 years OS and DFS was 40.8% and 49% respectively. Disease stage, operative procedure on primary tumor was an independent prognostic for both 5-year OS and DFS. The pN, surgical margin had a significant impact on OS. Conclusion: Adjuvant chemo-radiation may be an effective and safe regimen for patients who have undergone gastrectomy with curative intent in locally advanced stomach cancer and did not receive preoperative chemotherapy.